700 patients110,866 observations180 daysLIVE

Patient P-02320

Synthetic patientMETA-24 · Day 168 · 75+ · F · baseline S14Steering view · 3DOpen companion preview
Therapy response
Improving
Tolerance
Improving
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
94%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 META-24 startedBaseline state S14
  2. Day 47 NP-02 recommendedDietary Support Protocol NP-02
  3. Day 48 Patient acceptedStarted NP-02 in the companion
  4. Day 58 GI symptom burden −21% vs expectedDietary Support Protocol NP-02
  5. Day 64 Tolerance state changedUnstable → Improving
  6. Day 75 GI-04 recommendedGI Support Protocol GI-04
  7. Day 76 Patient declinedNot now
  8. Day 80 Trajectory diverged from predictionObserved response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 80.

Primary contributors, last 14 days
  • Inflammatory activity-12
  • Toxicity-8
  • Nutritional resilience+5
  • GI instability-4
  • Treatment adherence-3

What helped?

  • Dietary Support Protocol NP-02Day 47
    Result: symptom burden −21%
  • GI Support Protocol GI-04Day 75
    Declined by patient
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 89% showed improvement
  • median effect visible after 8 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes
Wearable
42 min
worsening · -3.8 vs previous 14 d
Sleep duration
Wearable
6.4 h
worsening · -0.3 vs previous 14 d
Energy level
Daily log
2.3/10
stable · -0.0 vs previous 14 d
Steps
Wearable
4,929
worsening · -356 vs previous 14 d
GI burden
Companion
64.8/100
worsening · +6.4 vs previous 14 d
Adherence
Companion
45.5 %
stable · +1.4 vs previous 14 d
Sleep quality
Wearable
31.5/100
worsening · -5.2 vs previous 14 d
Glucose, CGM daily mean
CGM
141 mg/dL
stable · +2.7 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards restoration · 27 from the failing basin, 67 from restoration.

Would help
  • GI-04 GI Support Protocol
    77% improved among 65 similar · onset 8 d · confidence 97%
  • ME-01 Monitoring Escalation
    100% improved among 42 similar · onset 3 d · confidence 78%
  • SC-12 Supportive Compound
    69% improved among 26 similar · onset 6 d · confidence 78%
  • More protein
    GI -4.4 next day on high-intake days · n 23
Would not help
  • Keep fat low
    GI +5.7 next day on high-intake days · n 19
  • Keep histamine low
    GI +4.7 next day on high-intake days · n 24
  • Keep caffeine low
    GI +4.4 next day on high-intake days · n 21
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Dietary fat load
    +5.7detractor · 95%
  • Histamine load
    +4.7detractor · 95%
  • Caffeine
    +4.4detractor · 95%
  • Protein
    -4.4supporter · 95%
  • Ultra-processed food
    +3.4detractor · 92%
  • Alcohol
    +0.6no signal · 15%
  • Simple carbohydrates
    -0.5no signal · 15%
  • Insoluble fibre
    -0.5no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Inflammatory signalling 85
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 61
    • WearableHRV 33 ms, trending down
  • Mucosal barrier integrity 80
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 65 and rising
  • Butyrate / short-chain fatty acid production 80
    • MicrobiomeButyrate capacity 34/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Drug metabolism and exposure 60
    • DNACYP2D6 poor metabolizer → higher exposure
    • BloodToxicity index 50
  • Autonomic recovery 45
    • WearableResting HR 82 bpm
    • WearableShort sleep window
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Poor metabolizer
    Higher exposure at standard dose
Microbiome
Shannon diversity 3.2 · butyrate capacity 34/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisHigh
  • Bifidobacterium longumLow
  • EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
HRV
29 ms
Sleep
6.5 h
Steps
3,528
Resting HR
84 bpm
Daily log: GI score 65, nutritional resilience 35, adherence 46.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the dose at the same time relative to your evening meal
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0248319%S06BR-03no change64
P-0256418%S15BR-03improved32
P-0202538%S15CR-01improved61
P-0215135%S04CR-01improved49
P-0205431%S01CR-01improved57
P-0200928%S08CR-01improved64
P-0215427%S16CR-01improved57
P-0223325%S16CR-01improved66
P-0239519%S12DT-01improved57
P-0249119%S09DT-01no change65
P-0227418%S15DT-01improved50
P-0233918%S03DT-01improved50